Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cytokinetics oral heart failure agent begins Phase I

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

After releasing top-line results of its Phase I intravenous CK-1827452 candidate to treat acute and chronic heart failure, Cytokinetics announced it will begin Phase I trials of an oral formulation of the compound. The company hopes to study the intravenous formulation in acutely decompensated heart failure patients in a hospital setting and transition them to an oral dose in an outpatient setting. Cytokinetics is already considering a sales force of 100-200 full-time employees for the drug (1Pharmaceutical Approvals Monthly August 2006, p. 6)...
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS003395

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel